Intracavernosal Injection (ICI) for Erectile Dysfunction

Intracavernosal injection therapy involves injecting a small dose of a vasodilating drug directly into the side of the penis to produce an erection, and it remains one of the most reliable treatments for erectile dysfunction when oral medications fail. In a large self-injection study of nearly 700 men, participants reported being able to have sexual activity after about 94 percent of injections, with both men and their partners rating the experience as satisfactory the vast majority of the time.¹ The therapy sits squarely as a second-line option, meaning it is typically tried after pills like sildenafil or tadalafil have not worked well enough, but before surgical options like a penile implant.

How the Injection Produces an Erection

An erection happens when smooth muscle inside the two spongy chambers of the penis (the corpora cavernosa) relaxes, allowing blood to rush in and fill the tissue. ICI bypasses the brain-to-nerve-to-blood-vessel chain that normally triggers this process and delivers a vasodilator straight to the target tissue. Because the drug is deposited locally, very little enters the general bloodstream, which is why systemic side effects are rare.²

The most commonly used drug is alprostadil, a synthetic form of prostaglandin E1. It binds to receptors on the smooth muscle cells, triggering an internal cascade that ultimately lowers calcium levels inside those cells. Lower calcium means the muscle relaxes, the blood flows in, and the penis becomes rigid. The erection typically begins within five to fifteen minutes and lasts long enough for intercourse, though duration varies with dose.

What Gets Injected

There are essentially two categories of ICI medication: single-agent alprostadil and combination mixtures.

Alprostadil alone is the only FDA-approved drug for intracavernosal use and is the most studied. A dose-response study of 296 men found that all doses tested (ranging from 2.5 to 20 micrograms) outperformed placebo, with response rates climbing as the dose increased.¹ However, the dose needed to produce a usable erection varies widely depending on the underlying cause. Men with nerve-related erectile dysfunction often respond to very low doses, while those with blood-vessel damage may need substantially more.

When alprostadil alone is not enough, clinicians commonly prescribe combination formulas, the most well-known being “trimix,” which blends alprostadil with papaverine and phentolamine. Each drug works through a slightly different pathway to relax smooth muscle, so the combination can succeed where a single agent falls short. In one prospective study, only a small number of men with erectile dysfunction responded adequately to a low dose of alprostadil alone, but 60 percent of that same group achieved a usable erection with a standard trimix dose.³ Trimix is not FDA-approved as a branded product; it is prepared by compounding pharmacies, which brings its own set of considerations around storage and quality.

Effectiveness Across Different Causes

The headline effectiveness number for ICI therapy is roughly 60 percent when measured by adequate penile rigidity across a broad patient population.⁴ That figure may sound modest compared to the 94 percent “able to have sex” number mentioned earlier, and the difference is worth understanding. The 94 percent figure comes from a self-injection study where doses were carefully titrated and participants were motivated enough to continue the protocol for six months. The 60 percent figure reflects a broader, more typical clinical population, including men whose erectile dysfunction is more severe. In practice, success depends heavily on the underlying cause and how carefully the dose has been optimized.

Men whose erectile dysfunction is primarily neurogenic, meaning the nerves controlling erection are intact but the signaling is disrupted, tend to respond at lower doses. Men with vascular damage, often related to diabetes, smoking, or cardiovascular disease, generally need higher doses and may be less likely to achieve full rigidity. In diabetic men specifically, age appears to matter more than the duration of diabetes or the presence of complications. One study of diabetic men found that 11 out of 19 patients under sixty had a satisfactory response, compared to just 1 out of 14 patients over sixty.⁵ That said, long-term data on diabetic men who stick with ICI therapy is encouraging: when doses are properly adjusted over time, self-injection remains safe and effective for years, with both type 1 and type 2 diabetic men showing similar treatment patterns after a decade of use.⁶

ICI After Prostate Cancer Surgery

One of the largest groups of ICI users are men recovering from radical prostatectomy. Even with nerve-sparing surgical techniques, erectile function is commonly damaged, and the recovery period can stretch over two years. ICI plays a dual role in this context: it provides a way to have erections during recovery, and it may help preserve the health of the erectile tissue by promoting blood flow and oxygenation while the nerves heal.

Whether early ICI use actually improves the odds of eventually recovering natural erections is an area where the evidence is suggestive but not yet definitive. A review of penile rehabilitation strategies found that starting treatment early appears better than doing nothing, but solid long-term randomized data proving lasting benefit from ICI, oral medications, or vacuum devices are still lacking.⁷ Still, a recent analysis found that roughly a third of men using ICI after prostatectomy regained functional erections without needing injections within two years of surgery, with higher baseline erectile function and lower injection doses being predictors of that recovery.⁸

Pain with the injection itself can be informative in this population. Men who underwent non-nerve-sparing surgery reported injection-related pain at dramatically higher rates (92 percent) compared to men who had bilateral nerve-sparing surgery (10 percent). The presence of pain with the injection also correlated with worse outcomes for eventually transitioning to oral medications.⁹ In other words, injection-related pain may serve as an indirect marker of nerve damage severity.

Pain and What the Injection Actually Feels Like

Fear of the needle is the single biggest psychological barrier to ICI. The reality is less dramatic than most people expect. The needle used is extremely fine, similar to an insulin syringe, and the injection goes into the side of the penile shaft while avoiding visible veins and the urethra. Most men describe the needle stick itself as minor.

The more common discomfort is a dull ache that comes after injection, caused by the alprostadil itself rather than the needle. In the large New England Journal of Medicine trial, penile pain occurred at some point in about half of the men using alprostadil, but it happened after only 11 percent of individual injections, meaning it was intermittent rather than a constant companion.¹ The pain is usually described as mild. Trimix combinations tend to cause less aching because the alprostadil dose is lower when combined with other agents.

Risks Worth Knowing About

The most serious risk with ICI is priapism, an erection that lasts more than four hours and does not resolve on its own. This is a medical emergency because prolonged engorgement can damage the erectile tissue. Among over 26,000 in-office ICI uses analyzed in a cross-sectional study, about 4 percent of patients experienced a priapism episode, with the vast majority occurring within the first three days after injection.¹⁰ The risk is highest during the initial dose-finding phase, which is why first injections are done in a doctor’s office under observation. Once a man has a stable, tested dose, priapism during home use is uncommon. The standard instruction is to seek emergency treatment if an erection lasts beyond four hours.

Penile scarring, sometimes called fibrosis, is the other concern that comes up frequently. Small nodules or plaques can form at injection sites over time. A study of 92 men using alprostadil found that about 16 percent developed some degree of scarring, but interestingly, the researchers could not identify a clear relationship between scarring and the total number of injections, dose per injection, or duration of use.¹¹ Men who already had scarring before starting therapy were not at significantly higher risk of developing more. Rotating injection sites between the left and right sides and avoiding injection into existing nodules are standard practices to reduce this risk.

Why People Stop

Despite good efficacy numbers, a significant portion of men eventually discontinue ICI. In a study of 720 men followed for an average of about three years, the overall dropout rate was 31 percent. The reasons, however, are not what most people assume. Lack of efficacy was the primary driver for only about one in seven dropouts. The actual main reasons were the cost of therapy, patient or partner discomfort with the concept of penile injection, lack of a sexual partner, and in some cases, spontaneous improvement in erections. Adverse effects like priapism, nodules, and pain were only minor contributors.¹²

This pattern matters because it suggests that the therapy works for most men who try it, but the psychological and financial burdens of ongoing self-injection eventually outweigh the benefit for some. Cost is a real issue: trimix is not always covered by insurance, and compounding pharmacy prices vary significantly. A man injecting two or three times per week will spend considerably more per year than someone using it once a week.

How ICI Compares to Other Options

Oral PDE5 inhibitors like sildenafil and tadalafil are tried first for good reason: they are easier to use, non-invasive, and effective for a majority of men. ICI enters the picture when pills fail or are contraindicated, which happens more often than the public realizes, particularly in men with diabetes, after prostate surgery, or in those taking certain cardiac medications.

When ICI is compared head-to-head with intraurethral alprostadil (MUSE), which delivers the same drug as a pellet inserted into the urethra rather than by injection, ICI wins on effectiveness. In a randomized study, 90 percent of men achieved a good erection with intracavernosal alprostadil versus 60 percent with the intraurethral version. Intercourse rates during three months of home use were 85 percent per dose for injection versus 55 percent for MUSE. The tradeoff is convenience: 90 percent of MUSE users rated home treatment as easy, compared to 40 percent of injection users.¹³

On the other end of the spectrum, penile prosthesis implantation is a surgical option that consistently scores higher on patient and partner satisfaction surveys. In one study, satisfaction scores were significantly higher in the prosthesis group compared to ICI, and men with prostheses remained sexually active longer, with a mean use duration of 63 months compared to 37 months for injection users.¹⁴ Another study confirmed this pattern, finding that prosthesis recipients scored meaningfully higher on treatment satisfaction indexes than men using ICI or daily tadalafil.¹⁵ Of course, a prosthesis requires surgery, is irreversible, and carries its own risks, so it is generally reserved for men who have exhausted less invasive options or who prefer a permanent solution.

Sexual Satisfaction and the Partner’s Experience

Satisfaction data from ICI users is generally positive when the treatment is working well. Men using ICI reported significant increases in intercourse satisfaction and overall sexual function scores, and one study found that achieving a fully rigid erection was by far the strongest predictor of satisfaction, with an odds ratio of nearly 7 compared to men who achieved only partial rigidity.¹⁶ Earlier research found that self-injection treatment was associated with improvements not just in erection quality but also in intercourse frequency, sexual satisfaction, relationship satisfaction, and self-esteem for the men using it.¹⁷

The partner’s experience is more complicated. Partners of men using ICI after prostatectomy reported low overall sexual quality of life, though their satisfaction was closely tied to how well the injections worked for their partner. Injection-related pain, the man’s age, and urinary problems all negatively affected the female partner’s sexual experience.¹⁸ Some partners struggle with the concept of injection-assisted sex more than the men themselves do, which is one reason couple-based counseling is often recommended alongside ICI therapy.

Practical Concerns With Compounding and Storage

Alprostadil as a single-agent injectable comes in commercially manufactured, FDA-approved formulations. Trimix, however, must be prepared by a compounding pharmacy because no manufacturer produces it as a finished product. This means quality can vary between pharmacies. California’s regulatory changes around sterile compounding, for example, prompted pharmacies to conduct stability studies to verify how long their trimix formulations remain effective after preparation.¹⁹

Trimix requires refrigeration and has a limited shelf life, typically measured in weeks to a few months depending on the formulation and pharmacy. Men who use it infrequently may find that a vial expires before they finish it. Freezing can extend the usable period, but not all formulations tolerate freeze-thaw cycles equally well. Your prescribing physician or pharmacist should provide specific storage instructions for the particular formulation dispensed.

Needle-Free Devices and Emerging Approaches

For men whose primary objection to ICI is the needle itself, needle-free injection devices represent an intriguing option. These devices use a high-pressure mechanism to push the medication through the skin without a needle tip. Research supports the potential feasibility of these devices for delivering ICI medications, and they may broaden access for men who refuse or abandon injection therapy because of needle phobia.²⁰ While not yet widely adopted, they are commercially available and worth asking about if fear of the needle is a dealbreaker.

On the more experimental side, researchers are investigating intracavernosal injection of mesenchymal stem cells for diabetic erectile dysfunction. Animal studies have shown improvements in blood flow ratios and increases in the markers of healthy erectile tissue, and early human studies have reported improvements in erectile function scores and erection hardness.²¹ These approaches are years from clinical availability, but they point toward a future where the injection route could deliver regenerative therapies, not just temporary vasodilators.